Kygevi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback